KORU Medical Systems Earnings Call Transcripts
Fiscal Year 2026
-
Q2 revenue grew 18% year-over-year to $12M, with strong domestic and international expansion and a return to positive net income. Guidance was narrowed due to international launch timing, but gross margin outlook was raised and long-term growth catalysts remain robust.
-
Q1 2026 delivered 22% revenue growth, strong domestic and international expansion, and improved profitability metrics. Guidance for the full year is reiterated, with expectations for continued growth, positive cash flow, and margin improvement as new markets and products ramp.
Fiscal Year 2025
-
Revenue grew 22% year-over-year to $41.1M in 2025, with strong domestic and international gains, positive adjusted EBITDA, and cash flow. 2026 guidance projects 15%–22% revenue growth, continued profitability, and new product launches, amid a CEO transition.
-
Year-to-date growth exceeded 20%, fueled by international expansion, U.S. market outperformance, and prefill technology. New drugs and products are set to drive further gains, with margin improvement and cash flow positivity supporting a robust outlook.
-
Q3 revenue grew 27% year-over-year, led by strong SCIG and international expansion, with gross margin at 60.2%. Full-year guidance was raised to $40.5M-$41M, and 2026 growth is expected to remain above 20%. Oncology and prefilled conversions are key future drivers.
-
Strong recurring revenue, international expansion, and new product launches are driving 20%+ growth, with four new drugs expected to be approved in the next year and a robust pipeline targeting oncology and rare diseases. International growth and product innovation remain key priorities.
-
Q2 revenue grew 21% to $10.2M, driven by strong domestic and international performance, with raised 2025 guidance to $39.5–$40.5M. Gross margin remains robust despite tariff pressures, and positive cash flow is expected for the year. International expansion and new product launches are key growth drivers.
-
Record Q1 revenue grew 18% year-over-year, driven by strong core and international business. Guidance for 2025 was raised, with gross margin improvement and positive cash flow expected. Pipeline expansion and new market wins position the company for sustained growth.
Fiscal Year 2024
-
Record 2024 revenue growth of 18% was driven by strong domestic and international performance, margin expansion, and new collaborations. 2025 guidance projects 13–16% revenue growth, stable gross margins, and positive cash flow, with new product launches and international expansion as key drivers.
-
Double-digit growth and cash flow positivity are on track, driven by U.S. market rebound, 30%+ international growth, and expansion in novel therapies. Strategic partnerships, new product launches, and a focus on operational efficiency support a pathway to $50+ million revenue by 2026.
-
Q3 revenue grew 17% year-over-year to $8.2M, with double-digit gains across all segments and a 276% surge in novel therapies. Gross margin rose to 63.4%, and guidance for revenue, margin, and cash was raised. Cash flow break-even is expected in Q4, with strong momentum into 2025.
-
The conference highlighted strong growth in subcutaneous drug delivery, with a robust core IG business, rapid international expansion, and a pipeline of new drugs expected to drive significant revenue by 2026. Financials show improved margins and a path to profitability by 2025.
-
Record Q2 revenues grew 22% year-over-year, driven by strong domestic and international core business and novel therapies. Gross margin improved to 65%, and 2024 guidance was raised for both revenue and margin, with cash flow break-even expected in Q4.